Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Wraps Up MediChem Acquisition

NEW YORK, March 18 - DeCode Genetics on Monday said it has sealed its acquisition of MediChem Life Sciences as shareholders "voted overwhelmingly" to support the stock-for-stock deal.

All other closing conditions have also been met, DeCode said.

Under the terms of the acquisition, announced in January, MediChem shareholders will receive 0.3099 shares of newly issued DeCode common stock in exchange for each share of MediChem common stock they hold.

The Icelandic population genetics company said it expects to issue some 8.4 million new shares of common stock, bringing to 53.6 million shares it will have outstanding.

"With the addition of MediChem's proven expertise in medicinal chemistry and proteomics, DeCode is becoming a fully integrated biopharmaceutical company with the capacity to take our population-validated targets into proprietary drug discovery and development," Kari Stefansson, CEO of DeCode, said in a statement.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.